



Personalized Medicine in Skull Base and Sinonasal Tumors

Guest Editors:

Dr. Davide Mattavelli

Unit of Otorhinolaryngology—
Head and Neck Surgery,
Department of Medical and
Surgical Specialties, Radiological
Sciences, and Public Health,
ASST Spedali Civili of Brescia,
University of Brescia, Brescia,
Italy

Dr. Paolo Bossi

Unit of Medical Oncology,
Department of Medical and
Surgical Specialties, Radiological
Sciences and Public Health, ASST
Spedali Civili of Brescia,
University of Brescia, Brescia,
Italy

Deadline for manuscript
submissions:

closed (5 March 2024)

Message from the Guest Editors

In recent decades, multidisciplinary approaches and innovations in treatments (such as endoscopic surgery and heavy ion irradiation) have improved outcomes in sinonasal and skull base tumors. However, a relevant proportion of patients still bears a poor prognosis despite the intensified regimen of treatment. Tumor biology largely drives prognosis in this subset of patients, while the rarity of these tumors, together with their great histologic variety, hinders a more accurate definition of tumor profiles. Multi-omics analysis could largely improve our understanding of these diseases and provide us with biomarkers to better depict these tumors at multiple levels: diagnosis, prognostic stratification, and the prediction of response to treatment. Likewise, they can identify therapeutic targets to inspire new pharmaceutical options. In this regard, the tumor–host interplay, immune contexture, and immunotherapy are still to be investigated in sinonasal and skull base tumors, representing a new therapeutic frontier to explore.

Overall, such studies can possibly pave the way towards a more effective, less toxic, personalized therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)